Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) Short Interest Update

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) was the recipient of a large increase in short interest in November. As of November 29th, there was short interest totalling 2,920,000 shares, an increase of 11.5% from the November 14th total of 2,620,000 shares. Approximately 3.3% of the shares of the stock are short sold. Based on an average trading volume of 347,900 shares, the short-interest ratio is presently 8.4 days.

Several large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC raised its holdings in shares of Adaptimmune Therapeutics by 25.7% in the 2nd quarter. SG Americas Securities LLC now owns 23,259 shares of the biotechnology company’s stock valued at $94,000 after acquiring an additional 4,752 shares in the last quarter. Bamco Inc. NY raised its holdings in shares of Adaptimmune Therapeutics by 6.1% during the 2nd quarter. Bamco Inc. NY now owns 172,669 shares of the biotechnology company’s stock valued at $694,000 after buying an additional 10,000 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Adaptimmune Therapeutics by 21,372.0% during the 3rd quarter. Tower Research Capital LLC TRC now owns 21,472 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 21,372 shares in the last quarter. Aperio Group LLC purchased a new position in shares of Adaptimmune Therapeutics during the 2nd quarter valued at about $88,000. Finally, Acadian Asset Management LLC raised its holdings in shares of Adaptimmune Therapeutics by 119.5% during the 2nd quarter. Acadian Asset Management LLC now owns 42,517 shares of the biotechnology company’s stock valued at $170,000 after buying an additional 23,143 shares in the last quarter. 65.06% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:ADAP opened at $1.22 on Friday. The business’s 50-day moving average price is $0.97 and its two-hundred day moving average price is $2.08. Adaptimmune Therapeutics has a twelve month low of $0.71 and a twelve month high of $6.31. The stock has a market cap of $127.72 million, a P/E ratio of -1.27 and a beta of 1.83. The company has a quick ratio of 3.93, a current ratio of 3.93 and a debt-to-equity ratio of 0.15.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.03). The business had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $7.00 million. On average, equities research analysts expect that Adaptimmune Therapeutics will post -1.37 EPS for the current fiscal year.

Several analysts have weighed in on ADAP shares. ValuEngine raised Adaptimmune Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, December 3rd. Cowen reaffirmed a “buy” rating on shares of Adaptimmune Therapeutics in a report on Thursday, November 7th. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $5.69.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.

Featured Story: What is the CAC 40 Index

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.